Zoetis Inc. (ZTS) fair value analysis

S&P 500 · Updated 2026-09-07

Zoetis Inc. is a pharmaceutical company that discovers, develops, manufactures, and distributes medicines and vaccines for animals, including both companion animals such as dogs and cats and livestock such as cattle and poultry. The company operates globally across multiple continents, serving veterinarians, farmers, and animal owners in markets around the world.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, ZTS is trading at more than a 25% discount to estimated fair value.

ZTS currently ranks #5 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $75.81
Sector: Healthcare
12-month range: $77.10–$144.35

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Moderate
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
52-week position: The bottom quarter of its range
DCF cross-check: Undervalued

What our data shows for ZTS

Our model validated 17 trailing price-to-earnings windows for ZTS, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $77.10–$144.35.
The 14-day relative strength index sits at a neutral 51.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ZTS
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ZTS news

TickrTrends' derived news-sentiment signal for ZTS is currently leaning positive, computed from recent coverage.

Zoetis (ZTS) Shares Drop After Earnings Revision (finance.yahoo.com, 2026-09-08)
TickrTrends take: Zoetis shares declining following an earnings revision occurs within a context where TickrTrends currently identifies the stock as undervalued. For valuation-focused investors, this price movement presents an opportunity to assess whether the earnings revision has fundamentally altered the company's worth relative to its Healthcare sector peers, or whether the decline has created a wider gap between market price and underlying value. Monitoring how the market digests this revision against ZTS's Healthcare sector positioning will be important for determining whether the undervalued designation remains appropriate.
Is Zoetis Stock Underperforming the S&P 500? (finance.yahoo.com, 2026-09-03)
TickrTrends take: Zoetis operates in the Healthcare sector where TickrTrends currently derives an undervalued assessment for the stock. A valuation-focused reader should monitor whether the company's recent underperformance relative to the S&P 500 represents a temporary market inefficiency or signals deteriorating fundamentals that could challenge the undervalued designation. The gap between market performance and valuation assessment may present an opportunity for investors tracking discrepancies between price action and intrinsic value metrics.
Is It Too Late to Buy Zoetis Inc (ZTS) After 3.1% Rally? GF Value Says Undervalued (gurufocus.com, 2026-08-28)
TickrTrends take: Zoetis Inc trades in the Healthcare sector where valuation metrics significantly influence investment decisions, and TickrTrends currently rates the stock as undervalued based on its analytical framework. The recent rally described in the headline occurs against this undervalued backdrop, suggesting the stock may retain margin of safety for valuation-conscious investors despite its recent price movement. Readers tracking valuation should monitor whether ZTS continues to trade below its calculated intrinsic value threshold or whether the rally narrows that gap.

What people are saying

Follow the ZTS conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — # ZTS Weekly Indicator Summary TickrTrends' derived indicators for ZTS have shifted this week, with the DCF cross-check band moving from fairly valued to undervalued. This change aligns with the current valuation verdict that categorizes the stock as undervalued. The movement in the DCF cross-check band suggests that fundamental value assessments have become more favorable relative to the current market price.
2026-09-06 — TickrTrends' derived indicators for ZTS showed mixed movement this week. The DCF cross-check band improved from an overvalued assessment to fairly valued, while the momentum indicator declined from a B rating to none. The current valuation verdict for the Healthcare sector company remains Undervalued.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ZTS stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ZTS is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is ZTS's TickrTrends verdict?

ZTS's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does ZTS compare to other Healthcare stocks?

ZTS ranks #5 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ZTS overbought or oversold?

ZTS's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ZTS vs ADMA · ZTS vs ALGN · ZTS vs ASTH · ZTS vs AZN · ZTS vs BSX